China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with compatriot firm Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) concerning the drug Xpovio (selinexor). This agreement outlines the roles and responsibilities of both companies in the Chinese market.
Responsibilities and Financial Terms of the Agreement
According to the agreement, Antengene will take the lead on research and development, regulatory filing, product supply, and distribution of Xpovio in mainland China. Hansoh, on the other hand, will be responsible for the commercialization efforts. As part of the deal, Hansoh will pay Antengene an upfront fee of RMB 200 million (USD 27.8 million) and is committed to paying up to RMB 535 million (USD 74.2 million) in milestone payments, in addition to sales royalties and service fees.
Xpovio: The First and Only FDA-Approved Oral XPO1 Inhibitor
Xpovio, discovered by US-based Karyopharm Therapeutics Inc. (Nasdaq:KPTI), is the world’s first and only FDA-approved oral XPO1 inhibitor. It is utilized in the treatment of hematological malignancies. Karyopharm had previously licensed the rights for the drug to Antengene for distribution in Greater China, South Korea, and ASEAN countries in May 2018. Xpovio received conditional approval in China in November 2021 for use in adult patients with relapsed/refractory multiple myeloma (R/R MM), specifically in those who have been previously treated with one other therapy.-Fineline Info & Tech
